Pulmonary Embolism Drugs Market Size

Pulmonary Embolism Drugs Market size was valued at USD 1.76 billion in 2024 and is set to cross USD 3.85 billion by the end of 2037, expanding at more than 6.1% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of pulmonary embolism drugs is estimated at USD 1.84 billion.

The growth of the market can be attributed to the increasing prevalence of cardiovascular diseases owing to the malfunction of arteries. Cardiovascular diseases are associated with blood vessels or the heart. It is a medical condition in which the circulation of blood to the brain, heart, and body is reduced owing to blood clots. Based on the data provided by the World Health Organization (WHO), in 2019, around 17.9 million people were observed to be suffering from cardiovascular disease.

In addition to these, global market trends such as, rising awareness of healthy lifestyles promoting the importance of early diagnosis and a surge in the cases of cancer are estimated to expand the market size over the forecast period. Pulmonary embolism is observed to cause a significant number of cancers in the global population. For instance, around 5% of cancer-related deaths are accounted by pulmonary emboli which is a type of blood clot in the lungs. Furthermore, people suffering from cancer associated with the brain, lungs, stomach, and people who are noticed to be undergoing chemotherapy are at higher risk of getting pulmonary embolism. For instance, it was projected that there is estimated to be around 22 million cancer survivors owing to chemotherapy by the year 2032. Hence, all these factors are anticipated to influence the market growth positively over the forecast period.